ProGnosis Biotech

Executive Summary

ProGnosis Biotech is a private European diagnostics company headquartered in Athens, Greece, specializing in the development and manufacturing of in-vitro diagnostic (IVD) tests. Founded in 2015, the company offers ELISA and Lateral Flow Assay kits primarily for food safety (mycotoxins, allergens, GMOs), hygiene monitoring, and clinical diagnostics (infectious diseases). ProGnosis is committed to accuracy, sustainability, and global safety compliance, serving markets that require reliable and rapid testing solutions. Despite its niche focus, the company operates in a competitive landscape dominated by larger players. With no disclosed funding or revenue data, ProGnosis appears to be a bootstrapped or early-stage firm, limiting its scalability. However, its specialization in food safety diagnostics aligns with growing regulatory demands and consumer awareness, providing a potential growth avenue. The company's private status and lack of significant milestones suggest limited near-term visibility, but its product portfolio could attract strategic partnerships or acquisition interest from larger diagnostics firms seeking to expand into the European food testing market.

Upcoming Catalysts (preview)

• Q1 2027Launch of next-generation mycotoxin testing kits with enhanced sensitivity40% success
• Q4 2026Strategic partnership with a global food safety distributor for EU market expansion30% success
• Q3 2026CE-IVD certification for a new infectious disease diagnostic panel50% success